SOURCE: Neuroscience and Behavioral Physiology. (no pagination), 2023.
DATE OF PUBLICATION: 2023.
AUTHORS: Prosvetov A.O.; Tsygankov B.D.; Guekht A.B.; Kuznetsov E.V.; Less U.E.; Tumurov D.A.; Popov G.R.; Tsygankov D.B.; Rangus S.R.
ABSTRACT: The prevalence of affective disorders in patients with Parkinson’s disease (PD) is significantly higher than that in the general population of people of the same age. The efficacy of antidepressants in PD with depressive disorder is known to be lower than in patients with primary depression. Other therapeutic strategies are available in cases of depression refractory to standard pharmacotherapy. Transcranial magnetic stimulation is one of the most popular and safe methods of brain stimulation and has been used with success to treat primary depression. The accumulation of experience in the use of transcranial magnetic stimulation has allowed the application of this method to be expanded to other nosologies, including PD. This article reflects published data on the use of different transcranial magnetic stimulation protocols for the treatment of depressive disorder in patients with PD.
LINK TO FULL ARTICLE: https://link.springer.com/article/10.1007/s11055-023-01450-4